Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to treat gout, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AR882 for the potential treatment of clinically visible tophi in patients with gout.

"Receiving Fast Track designation for AR882 from the FDA marks a significant milestone for Arthrosi. This  highlights the FDA's recognition of the serious and disabling nature of gout in patients with clinically visible tophi and the potential of AR882 to meet this critical medical need," said Litain Yeh, Ph.D.  Founder and CEO of Arthrosi Therapeutics. "With our pivotal Phase 3 clinical program underway, we are committed to working closely with the FDA to accelerate the development of AR882."

Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

 

Source:prnewswire.com

Report Abuse